Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: The present invention relates to a method of diagnosing pulmonary hypertension (PH) in a patient, a method of monitoring the course of pulmonary hypertension in a patient, a method of determining the severity of pulmonary hypertension in a patient, and a method of differentiating between pulmonary hypertension and at least one condition selected from a group consisting of a disease associated with a risk of developing pulmonary hypertension and metabolic syndrome. In addition, the present invention relates to a kit comprising means for carrying out the above methods.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: The present invention relates to a method of diagnosing pulmonary hypertension (PH) in a patient, a method of monitoring the course of pulmonary hypertension in a patient, a method of determining the severity of pulmonary hypertension in a patient, and a method of differentiating between pulmonary hypertension and at least one condition selected from a group consisting of a disease associated with a risk of developing pulmonary hypertension and metabolic syndrome. In addition, the present invention relates to a kit comprising means for carrying out the above methods.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: The invention relates to a device (10) and method for processing images (1) of the pulmonary circulation (2) of a living being in order to characterize the arterial blood flow, wherein a plurality of temporally successive images (1) are processed, said device having a selection interface (12) containing at least two defined locations (a, b, c) of an image (1), a unit (13) for assigning the at least two defined locations (a, b, c) to all images (1), a unit (14) for determining the density (D) at at least two defined locations (a, b, c) in all images (1), a unit (14) for calculating the density (D) for the defined locations (a, b, c) as a function (Fa, fa, fb, fc) of time (t), a unit (16) for analysing the at least one time difference (?b, ?c) between the maximum values (Ma, Mb, Mc) of the density (D) for the at least two defined locations (a, b, c) as a function of time (t), and a display (17) for the at least one time difference (?b, ?c).

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: In a method and apparatus for examination and evaluation of a blood flow in a pulmonary artery of a patient, measurement data are recorded, from which at least a part of the blood flow in the pulmonary artery is able to be re-constructed at least two-dimensionally in a plane defined by a longitudinal axis of the pulmonary artery and by an anterior-posterior direction, including at least at several diastolic points in time in the course of a heart cycle, after a closure of the pulmonary valve. The number of diastolic points for which an asymmetry in relation to the longitudinal axis of the pulmonary artery in the anterior-posterior direction exists is determined. A measure is then determined that characterizes how long, after the closure of the pulmonary valve, the aforementioned asymmetry exists.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: In a method and apparatus for examination and evaluation of a human or animal body as regards a blood flow in a pulmonary artery (PA), measurement data are recorded, from which at least a part of the blood flow in the pulmonary artery (PA) is able to be re-constructed at least two-dimensionally in a plane defined by a longitudinal axis of the pulmonary artery (PA) and by an anterior-posterior direction, including at least at several diastolic points in time in the course of a heart cycle, after a closure of the pulmonary valve. The measurement data are analyzed as to how many of the at least several diastolic points in time in the flow behavior of the blood flow of the pulmonary artery an asymmetry in relation to the longitudinal axis of the pulmonary artery in the anterior-posterior direction exists. A measure is then determined that characterizes how long, after the closure of the pulmonary valve in the flow behavior of the blood flow of the pulmonary artery, the aforementioned asymmetry exists.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.